Welcome, Guest. Please login or register.
December 30, 2024, 11:29:31 am

Login with username, password and session length


Members
  • Total Members: 6315
  • Latest: DRG
Stats
  • Total Posts: 55137
  • Total Topics: 4855
  • Online Today: 284
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 249
Total: 249

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Those on Daklinza-Based Hep C Regimens Do Well  (Read 4645 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Those on Daklinza-Based Hep C Regimens Do Well
« on: July 25, 2018, 11:47:32 am »
People who are treated for hepatitis C virus (HCV) with Daklinza (daclatasvir)-based regimens tend to do very well going forward, according to a new large study that followed such individuals long term.

Publishing their findings in Liver International, researchers enrolled 1,503 people starting in February 2012 who had just been treated with Daklinza-based regimens. The participants were followed for a median 111 weeks after the 12-week posttreatment mark; the study ended follow-up in October 2015.

For more...
https://www.hepmag.com/article/daklinzabased-hep-c-regimens

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.